Interferon-free regimens improve health-related quality of life and fatigue in HIV/HCV-coinfected patients with advanced liver disease

Medicine (United States)

Volumn 95, Issue 27, 2016, Pages

  Scheiner, Bernhard ^a,b   Schwabl, Philipp ^a,b   Steiner, Sebastian ^a,b   Bucsics, Theresa ^a   Chromy, David ^a   Aichelburg, Maximilian C ^b   Grabmeier Pfistershammer, Katharina ^b   Trauner, Michael ^a   Peck Radosavljevic, Markus ^a,b   Reiberger, Thomas ^a,b   Mandorfer, Mattias ^a,b  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b Universitatsklinik fur Dermatologie   (Austria)

Author keywords

boceprevir PEGIFN RBV treatment; health related quality of life; HIV HCV coinfection; interferon free HCV treatment

Indexed keywords

BOCEPREVIR; DACLATASVIR; LEDIPASVIR PLUS SOFOSBUVIR; PEGINTERFERON; RIBAVIRIN; SOFOSBUVIR; ANTIVIRUS AGENT; BENZIMIDAZOLE DERIVATIVE; BMS-790052; FLUORENE DERIVATIVE; IMIDAZOLE DERIVATIVE; LEDIPASVIR;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; AIDS PATIENT; ANTIVIRAL THERAPY; ARTICLE; CLINICAL ARTICLE; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; DISEASE SEVERITY; DRUG TOLERABILITY; FATIGUE; FATIGUE SEVERITY SCALE; FEMALE; HEALTH; HEPATIC ENCEPHALOPATHY; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIVER DISEASE; MALE; MENTAL HEALTH; MIDDLE AGED; MIXED INFECTION; PRIORITY JOURNAL; QUALITY OF LIFE; RETROSPECTIVE STUDY; SHORT FORM 36; AUSTRIA; HEPATITIS C, CHRONIC; HIV INFECTIONS; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

ANTIVIRAL AGENTS; AUSTRIA; BENZIMIDAZOLES; COINFECTION; FATIGUE; FEMALE; FLUORENES; HEPATITIS C, CHRONIC; HIV INFECTIONS; HUMANS; IMIDAZOLES; MALE; MIDDLE AGED; QUALITY OF LIFE; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; SOFOSBUVIR; TREATMENT OUTCOME;

EID: 84978682895     PISSN: 00257974     EISSN: 15365964     Source Type: Journal    
DOI: 10.1097/MD.0000000000004061     Document Type: Article

References (51)

1. Alter MJ. Epidemiology of viral hepatitis and HIV co-infection. J Hepatol 2006;44:S6-9
2. Graham CS, Baden LR, Yu E, et al. Influence of human immunodeficiency virus infection on the course of hepatitis C virus infection: a metaanalysis. Clin Infect Dis 2001;33:562-9
3. Reiberger T, Ferlitsch A, Sieghart W, et al. HIV-HCV co-infected patients with low CD4+ cell nadirs are at risk for faster fibrosis progression and portal hypertension. J Viral Hepat 2010;17:400-9
4. Garcia-Samaniego J, Rodriguez M, Berenguer J, et al. Hepatocellular carcinoma in HIV-infected patients with chronic hepatitis C. Am J Gastroenterol 2001;96:179-83
5. Reiberger T, Obermeier M, Payer BA, et al. Considerable undertreatment of chronic HCV infection in HIV patients despite acceptable sustained virological response rates in a real-life setting. Antivir Ther 2011;16:815-24
6. Mandorfer M, Payer BA, Schwabl P, et al. Revisiting liver disease progression in HIV/HCV-coinfected patients: the influence of vitamin D, insulin resistance, immune status, IL28B and PNPLA3. Liver Int 2014;35:876-85
7. European Association for the Study of the LiverElectronic address eee. EASL Recommendations on Treatment of Hepatitis C 2015. J Hepatol 2015;63:199-236
8. Martin TC, Martin NK, Hickman M, et al. Hepatitis C virus reinfection incidence and treatment outcome among HIV-positive MSM. Aids 2013;27:2551-7
9. Cacoub P, Dabis F, Costagliola D, et al. Burden of HIV and hepatitis C co-infection: the changing epidemiology of hepatitis C in HIV-infected patients in France. Liver Int 2015;35:65-70
10. van Laar TJ, van der Bij AK, PrinsM, et al. Increase in HCV incidence among men who have sex with men in Amsterdam most likely caused by sexual transmission. J Infect Dis 2007;196:230-8
11. Fleming CA, Christiansen D, Nunes D, et al. Health-related quality of life of patients with HIV disease: impact of hepatitis C coinfection. Clin Infect Dis 2004;38:572-8
12. Mandorfer M, Payer BA, Scheiner B, et al. Health-related quality of life and severity of fatigue in HIV/HCV co-infected patients before, during, and after antiviral therapy with pegylated interferon plus ribavirin. Liver Int 2014;34:69-77
13. Payer BA, Reiberger T, Breitenecker F, et al. The risk of infections in HIVHCV coinfected patients during antiviral therapy with pegIFN+RBV. J Infect 2012;65:142-9
14. Reiberger T, Kosi L,Maresch J, et al. Mitochondrial toxicity is associated with virological response in patients with HIV and hepatitis C virus coinfection treated with ribavirin and highly active antiretroviral therapy. J Infect Dis 2010;202:156-60
15. Talal AH, LaFleur J, Hoop R, et al. Absolute and relative contraindications to pegylated-interferon or ribavirin in the US general patient population with chronic hepatitis C: results from a US database of over 45 000 HCV-infected, evaluated patients. Aliment Pharmacol Ther 2013;37:473-81
16. Wyles DL, Ruane PJ, Sulkowski MS, et al. Daclatasvir plus Sofosbuvir for HCV in patients coinfected with HIV-1. N Engl J Med 2015;373: 714-25
17. Naggie S, Cooper C, Saag M, et al. Ledipasvir and Sofosbuvir for HCV in patients coinfected with HIV-1. N Engl J Med 2015;373:705-13
18. Rockstroh JK, Nelson M, Katlama C, et al. Efficacy and safety of grazoprevir (MK-5172) and elbasvir (MK-8742) in patients with hepatitis C virus and HIV co-infection (C-EDGE CO-INFECTION): a non-randomised, open-label trial. The lancet HIV 2015;2:e319-27
19. Bailly F, Pradat P, Virlogeux V, Zoulim F. Antiviral therapy in patients with hepatitis C virus-induced cirrhosis. Dig Dis 2015;33:613-23
20. Mandorfer M, Steiner S, Schwabl P, et al. Response-guided boceprevirbased triple therapy in HIV/HCV-coinfected patients: the HIVCOBOCRGT study. J Infect Dis 2015;211:729-35
21. Mandorfer M, Schwabl P, Steiner S, et al. Interferon-free treatment with sofosbuvir/daclatasvir achieves sustained virologic response in 100% of HIV/HCV-coinfected patients with advanced liver disease. AIDS 2016;30:1039-47
22. Castera L, Vergniol J, Foucher J, et al. Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C. Gastroenterology 2005;128:343-50
23. Tarantino G, Citro V, Conca P, et al. What are the implications of the spontaneous spleno-renal shunts in liver cirrhosis? BMC Gastroenterol 2009;9:89
24. Tarantino G, Citro V, Esposito P, et al. Blood ammonia levels in liver cirrhosis: a clue for the presence of portosystemic collateral veins. BMC Gastroenterol 2009;9:21
25. Afdhal N, Zeuzem S, Kwo P, et al. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. N Engl J Med 2014;370:1889-98
26. Scheiner B, Mandorfer M, Schwabl P, et al. The impact of PNPLA3 rs738409 SNP on liver fibrosis progression, portal hypertension and hepatic steatosis in HIV/HCV coinfection. PloS one 2015;10:e0143429
27. Dalgard O, Egeland A, Skaug K, et al. Health-related quality of life in active injecting drug users with and without chronic hepatitis C virus infection. Hepatology 2004;39:74-80
28. Younossi ZM, Stepanova M, Nader F, et al. The patient's journey with chronic hepatitis C from interferon plus ribavirin to interferon-and ribavirin-free regimens: a study of health-related quality of life. Aliment Pharmacol Ther 2015;42:286-95
29. Foster GR, Goldin RD, Thomas HC. Chronic hepatitis C virus infection causes a significant reduction in quality of life in the absence of cirrhosis. Hepatology 1998;27:209-12
30. Ware JE, Kosinski M, Dewey JE. How to Score Version 2 of the SF-36® Health Survey. Lincoln, RI: QualityMetric Incorporated; 2000
31. Samsa G, Edelman D, Rothman ML, et al. Determining clinically important differences in health status measures: a general approach with illustration to the Health Utilities Index Mark II. PharmacoEconomics 1999;15:141-55
32. Spiegel BM, Younossi ZM, Hays RD, et al. Impact of hepatitis C on health related quality of life: a systematic review and quantitative assessment. Hepatology 2005;41:790-800
33. Rosa K, Fu M, Gilles L, et al. Validation of the Fatigue Severity Scale in chronic hepatitis C. Health Qual Life Outcomes 2014;12:90
34. Scott J, Rosa K, Fu M, et al. Fatigue during treatment for hepatitis C virus: results of self-reported fatigue severity in two Phase IIb studies of simeprevir treatment in patients with hepatitis C virus genotype 1 infection. BMC Infect Dis 2014;14:465
35. Kleinman L, Zodet MW, Hakim Z, et al. Psychometric evaluation of the fatigue severity scale for use in chronic hepatitis C. Qual Life Res 2000;9:499-508
36. World Medical A. World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA 2013;310:2191-4
37. Vilstrup H, Amodio P, Bajaj J, et al. Hepatic encephalopathy in chronic liver disease: 2014 Practice Guideline by the American Association for the Study of Liver Diseases and the European Association for the Study of the Liver. Hepatology 2014;60:715-35
38. From the Centers for Disease Control and Prevention. 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. JAMA 1993;269: 729-30
39. Mandorfer M, Schwabl P, Steiner S, et al. Advances in the management of HIV/HCV coinfection. Hepatol Int 2015;10:424-35
40. Orr JG, Homer T, Ternent L, et al. Health related quality of life in people with advanced chronic liver disease. J Hepatol 2014;61:1158-65
41. Younossi ZM, Stepanova M, Sulkowski M, et al. Sofosbuvir and ribavirin for treatment of chronic hepatitis C in patients coinfected with hepatitis C virus and HIV: the impact on patient-reported outcomes. J Infect Dis 2015;212:367-77
42. Younossi ZM, Stepanova M, Henry L, et al. Effects of sofosbuvir-based treatment, with and without interferon, on outcome and productivity of patients with chronic hepatitis C. Clin Gastroenterol Hepatol 2014;12: 1349-59. e1313
43. Younossi ZM, Stepanova M, Afdhal N, et al. Improvement of healthrelated quality of life and work productivity in chronic hepatitis C patients with early and advanced fibrosis treated with ledipasvir and sofosbuvir. J Hepatol 2015;63:337-45
44. Piche T, Gelsi E, Schneider SM, et al. Fatigue is associated with high circulating leptin levels in chronic hepatitis C. Gut 2002;51: 434-9
45. Teuber G, Schafer A, Rimpel J, et al. Deterioration of health-related quality of life and fatigue in patientswith chronic hepatitis C: Association with demographic factors, inflammatory activity, and degree of fibrosis. J Hepatol 2008;49:923-9
46. Monaco S, Mariotto S, Ferrari S, et al. Hepatitis C virus-associated neurocognitive and neuropsychiatric disorders: advances in 2015. World J Gastroenterol 2015;21:11974-83
47. Hashemi F, Fathi Ashtiani A, Mirminachi B, et al. Impact of hepatitis C virus infection on cognitive function in patients with covert hepatic encephalopathy. Hepat Mon 2015;15:e30507
48. Levula A, Wilson A, Harre M. The association between social network factors and mental health at different life stages. Qual Life Res 2015;25:1725-33
49. Arduino JM, Jiang Z, Shaughnessy M, et al. C-EDGE Co-infectino: Impact of 12-Week Oral Regimen of Elbasvir (EBR, MK-8742)/ Grazoprevir (GZR. MK-5172) on Patient-Reported Outcomes (PROs) in Treatment-Naïve PatientsWith HCV/HIV Co-infection AASLD Liver Meeting 2015; November 13-17, 2015 San Francisco CA 2015
50. Gerber L, Estep M, Stepanova M, et al. Effects of viral eradication with Ledipasvir and Sofosbuvir, with or without Ribavirin, on measures of fatigue in patients with chronic hepatitis C virus infection. Clin Gastroenterol Hepatol 2016;14:156-64. e153
51. Ascione A. Boceprevir in chronic hepatitis C infection: a perspective review. Ther Adv Chronic Dis 2012;3:113-21